Applications of tumor chip technology

Area of Science:

• Biotechnology
• Drug Discovery
• Oncology Research

Background:

• The cost of new drug development has escalated, exceeding $2.5 billion.
• FDA approval rates for drugs entering Phase I trials are low (9.6%), particularly for oncology (5.1%).
• Current in vitro drug screening models lack predictability for in vivo outcomes, leading to late-stage failures.

Purpose of the Study:

• To review the state-of-the-art in 3D tissue-engineered models for cancer research.
• To focus on the application of tumor-on-a-chip (tumor chip) models in preclinical drug development.
• To highlight the potential of tumor chip systems to improve anti-cancer drug development and clinical treatment.

Main Methods:

• Review of current 3D tissue-engineering models for cancer research.
• Focus on microphysiological systems (MPS) and tumor chip technologies.
• Analysis of the predictive capabilities of these models for in vivo outcomes.

Main Results:

• Microphysiological systems (MPS) offer a more predictive in vitro environment.
• Tumor chip models effectively mimic physiological and pathological cancer processes.
• These advanced models can potentially identify efficacy and toxicity earlier in the drug development pipeline.

Conclusions:

• Tumor chip systems represent a significant advancement in cancer research and drug development.
• Implementing these models can help mitigate the high failure rates in anti-cancer drug discovery.
• Microphysiological systems hold the potential to transform preclinical research and clinical management for cancer therapies.